
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Florbetaben
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : pharmtrace
Deal Size : Inapplicable
Deal Type : Inapplicable
Test-retest Study With [18F]FBB in Cardiac Amyloidosis
Details : Florbetaben is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2025
Lead Product(s) : Florbetaben
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : pharmtrace
Deal Size : Inapplicable
Deal Type : Inapplicable

[18F]PI-2620 Phase 3 Histopathological Study
Details : 18-F PI-2620 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
December 08, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 18-F PI-2620
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Walter Reed National Military Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 18-F PI-2620 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Concussion.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
April 20, 2022
Lead Product(s) : 18-F PI-2620
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Walter Reed National Military Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC
Details : 18-F PI2620 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Supranuclear Palsy, Progressive.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
January 12, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 18-F Florbetaben
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : pharmtrace klinische Entwicklung
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Details : 18-F Florbetaben is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
January 11, 2022
Lead Product(s) : 18-F Florbetaben
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : pharmtrace klinische Entwicklung
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 18-F PI2620
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Life Molecular Imaging
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 18-F PI2620 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
January 20, 2021
Lead Product(s) : 18-F PI2620
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Life Molecular Imaging
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : 18-F MNI-815 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
August 24, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 68-Ga RM2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 68-Ga RM2 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
June 29, 2015
Lead Product(s) : 68-Ga RM2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 18-F GP1
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Recipient : University of Zurich
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of a New Imagingtechnologie for Thrombosis
Details : 18-F GP1 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Aortic Aneurysm, Abdominal.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
June 11, 2015
Lead Product(s) : 18-F GP1
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Recipient : University of Zurich
Deal Size : Inapplicable
Deal Type : Inapplicable

PET Imaging of Intracranial Cancers With 18F-FSPG
Details : 18-F FSPG is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
February 25, 2015
